gallocatechol has been researched along with Cancer of Prostate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahl, A; Holly, JM; Patel, S; Perks, CM; Persad, R; Thomas, F | 1 |
| Choi, HK; Choi, KC; Jun, W; Kim, S; Kwak, J; Lee, J; Lee, YH; Park, HJ; Yoon, HG | 1 |
2 other study(ies) available for gallocatechol and Cancer of Prostate
| Article | Year |
|---|---|
Dihydrotestosterone sensitises LNCaP cells to death induced by epigallocatechin-3-Gallate (EGCG) or an IGF-I receptor inhibitor.
Topics: Blotting, Western; Catechin; Cell Death; Cell Line, Tumor; Dihydrotestosterone; DNA Replication; DNA, Neoplasm; Humans; Male; Neoplasm Proteins; Prostatic Neoplasms; Receptor, IGF Type 1; Thymidine | 2009 |
EGCG suppresses prostate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyltransferase activity.
Topics: Acetylation; Androgen Receptor Antagonists; Antineoplastic Agents; Apoptosis; Catechin; Cell Line, Tumor; Cell Proliferation; Chemoprevention; Histone Acetyltransferases; Humans; Male; Prostatic Neoplasms; Receptors, Androgen; Transcription, Genetic | 2012 |